Studies on the production and quality assurance of miniature 125I radioactive sources suitable for treatment of ocular and prostate cancers

Saxena, Sandeep K.; Shanta, A; Rajurkar, N. S.; Majali, M. A.

doi:10.1016/j.apradiso.2005.08.011

Cited by 25 publications

(10 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1] after quality assurance tests[5] were supplied by Radiopharmaceuticals Division of Bhabha Atomic Research Center, Mumbai (BARC). [67] Precise individual seed activity is a prerequisite for accurate dose calculations. In order to preclude dosimetric errors in the treatment planning study, seeds from only one batch were used in each case.…”

Section: Methodsmentioning

confidence: 99%

Brachytherapy of intra ocular tumors using ′BARC I-125 Ocu-Prosta seeds′: An Indian experience

Khetan

Gopal

Shanmugam

et al. 2014

Indian J Ophthalmol

View full text Add to dashboard Cite

Aim:To report our experience of brachytherapy using ‘BARC I-125 Ocu-Prosta seeds’ for the management of intraocular tumors with regard to tumor control, globe preservation visual outcome, and patient survival at Sankara Nethralaya, Chennai, India between September 2003 and May 2011.Materials and Methods:We reviewed records of 35 eyes of 35 patients who underwent ophthalmic brachytherapy between September 2003 and May 2011. Twenty-one cases had choroidal melanoma, nine had childhood retinoblastoma, two had adult-onset retinoblastoma, and there were one case each of vasoproliferative tumor, retinal angioma, and ciliary body melanoma. Brachytherapy was administered using a 15- or 20-mm gold plaque with or without a notch. Brachytherapy was the primary treatment modality in all tumors other than retinoblastoma, wherein brachytherapy was done post chemoreduction for residual tumor.Results:For choroidal melanomas, the mean radiation dose was 68.69 ± 15.07 (range, 47.72-94.2) Gy. The eye salvage rate was 13/20 (65%) and tumor control rate was 16/20 (80%) at an average follow-up of 24.43 ± 24.75 (range, 1.5-87.98) months. For retinoblastoma, the mean dose was 45.85 ± 3.90 (range, 39.51-50.92) Gy. The eye salvage rate and tumor control rate was 5/6 (83.3%) at an average follow-up of 38.36 ± 31.33 (range, 4.14-97.78) months. All eyes with retinoblastoma needed additional focal therapy for tumor control and eye salvage.Conclusion:The results of this retrospective study confirms that the use of ‘BARC I-125 Ocu-Prosta seeds’ in episcleral plaques to treat intraocular tumors offers a viable option for the management of intraocular cancers.

show abstract

Section: Methodsmentioning

confidence: 99%

Brachytherapy of intra ocular tumors using ′BARC I-125 Ocu-Prosta seeds′: An Indian experience

Khetan

Gopal

Shanmugam

et al. 2014

Indian J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…At the end of 48 hours, the total leached out radioactivity was assayed to determine the leachability of bare sources should be less than 0.01% of the total seed activity. The physico-chemical adsorption method [14] adapted by us was found to achieve this limit and thus complied with regulatory norms.…”

Section: Leachabilitymentioning

confidence: 98%

“…The variation in OD values at different positions should be ±10 %. Sources prepared by the physico-chemical adsorption methodology [14] in our laboratory has variation within ± 5% (Fig.12). …”

Section: Uniformity Of Activitymentioning

confidence: 99%

See 1 more Smart Citation

Development of Miniature 125I - Seeds for the Treatment of Prostate Cancer

Saxena¹,

Dash²

2011

Prostate Cancer - Original Scientific Reports and Case Studies

View full text Add to dashboard Cite

“…The Radiopharmaceuticals Division, Bhabha Atomic Research Centre (BARC) has successfully developed a technology for the production of indigenous 125 I brachytherapy sources for the treatment of ocular cancer patients in India[78] and assessed its dosimetry. [9] We describe our initial experience and learning curve using ‘BARC 125 I Ocu-Prosta seed’ for the treatment of intraocular tumors.…”

mentioning

confidence: 99%

Episcleral plaque brachytherapy using ′BARC I-125 Ocu-Prosta seeds′ in the treatment of intraocular tumors: A single-institution experience in India

Shah

Narendran

Selvaraj

et al. 2012

Indian J Ophthalmol

View full text Add to dashboard Cite

Context:To analyze the results of episcleral plaque brachytherapy using indigenous Bhabha Atomic Research Centre (BARC) Iodine-125 Ocu-Prosta seeds for the management of intraocular tumors from a single institute.AIM:To report our initial experience and learning curve on the use of ‘BARC I-125 Ocu-Prosta seeds’ for the management of intraocular tumors such as choroidal melanomas, retinoblastomas and vasoproliferative tumors (VPT).Materials and Methods:We retrospectively reviewed 13 eyes of 13 patients who underwent ophthalmic brachytherapy between May 2008 to March 2012. Nine cases had choroidal melanomas; three had retinoblastomas while one case had VPT.Results:For choroidal melanomas the average apical diameter before brachytherapy was 7.6 mm and average largest basal diameter was 12.1 mm, respectively, which reduced to 4.2 mm and 7.7 mm after the procedure at an average follow-up of 24 months (range 10-43 months). Retinoblastoma and VPT also showed good regression after brachytherapy.Conclusion:Plaque radiotherapy using 125I seeds can be performed under peribulbar anesthesia and provides a viable option for the management of intraocular cancer with minimal invasiveness and surgical complications. Patients in our studies experienced excellent local tumor control. With the availability of indigenous ‘BARC I-125 Ocu-Prosta seeds’ locally, cost effective ophthalmic brachytherapy can be performed in India.

show abstract

Studies on the production and quality assurance of miniature 125I radioactive sources suitable for treatment of ocular and prostate cancers

Cited by 25 publications

References 8 publications

Brachytherapy of intra ocular tumors using ′BARC I-125 Ocu-Prosta seeds′: An Indian experience

Brachytherapy of intra ocular tumors using ′BARC I-125 Ocu-Prosta seeds′: An Indian experience

Development of Miniature 125I - Seeds for the Treatment of Prostate Cancer

Episcleral plaque brachytherapy using ′BARC I-125 Ocu-Prosta seeds′ in the treatment of intraocular tumors: A single-institution experience in India

Contact Info

Product

Resources

About